The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin. RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target trial enrolled adults (≥18 years) with type 2 diabetes who were either insulin naïve and receiving oral antidiabetic drugs (OADs) (HbA1c = 7–11%) or previously on basal insulin ± OAD(s) (HbA1c = 7–10%). Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8–40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230). The primary outcome was noninferiority of IDeg OD Flex to IGlar OD in HbA1c reduction after 26 weeks. RESULTS: After 26 weeks, IDeg OD Flex, IDeg OD, and IGlar OD improved HbA1c by 1.28, 1.07, and 1.26% points, respectively (estimated treatment difference [IDeg OD Flex − IGlar OD]: 0.04% points [–0.12 to 0.20], confirming noninferiority). No statistically significant differences in overall or nocturnal hypoglycemia were found between IDeg OD Flex and IGlar OD. Comparable glycemic control and rates of hypoglycemia were seen with IDeg OD Flex and IDeg OD. Adverse event profiles were similar across groups. CONCLUSIONS: The use of extreme dosing intervals of 8–40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“two treat-to-target, randomised studies where extreme dosing intervals of 8–40 h were used in subjects with T1DM and T2DM over a treatment duration of 26–52 weeks [49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“the concentration of IDeg-specific antibodies and antibodies cross-reacting with IDeg and human insulin was found to be low in studies in patients with T1DM [48, 49] or T2DM [50, 53], indicating that the risk of immunogenicity with IDeg is minimal.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“the studies showed that there was no apparent association between the development of cross-reacting antibodies and hypoglycaemia, HbA1c or insulin dose [48, 49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [53]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
(2009) · JIBL · doi:10.1515/jibl.2009.12 · Cited by 768
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Self-citationMire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Research works printed but not linked: 3
- International Diabetes Federation, 2011, Diabetes Atlas
- Heise, 2011, Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract), Diabetologia, 54, S425
- Kurtzhals, 2011, Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract), Diabetologia, 54, S426
Cited by
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
Self-citationThe evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
Heise, T., Hövelmann, U., Nosek, L., Hermanski, L., Bøttcher, S. G., & Haahr, H. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1058779 · Cited by 152
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135
Strain, W. D., Hope, S. V., Green, A., Kar, P. S., Valabhji, J., & Sinclair, A. J. (2018) · Diabetic Medicine · doi:10.1111/dme.13644 · Cited by 129
Rosenstock, J., Hollander, P., Bhargava, A., Ilag, L. L., Pollom, R. K., Zielonka, J. S., Huster, W. J., & Prince, M. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12482 · Cited by 111
Fulcher, G. R., Christiansen, J. S., Bantwal, G., Polaszewska-Muszynska, M., Mersebach, H., Andersen, T. H., & Niskanen, L. K. (2014) · Diabetes Care · doi:10.2337/dc13-2908 · Cited by 110
Heise, T., & Mathieu, C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12782 · Cited by 106
Onishi, Y., Iwamoto, Y., Yoo, S. J., Clauson, P., Tamer, S. C., & Park, S. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12102 · Cited by 102
Basal insulin analogues in the management of diabetes mellitus: what progress have we made?
Owens, D. R., Matfin, G., & Monnier, L. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2469 · Cited by 108
Vora, J., Christensen, T., Rana, A., & Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0076-9 · Cited by 96
Self-citationThalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A., Kinduryte, O., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12263 · Cited by 91
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89
Evolution of Insulin: From Human to Analog
Tibaldi, J. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.005 · Cited by 107
The past, present, and future of basal insulins
Pettus, J., Cavaiola, T. S., Tamborlane, W. V., & Edelman, S. V. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2763 · Cited by 93
Kaneko, S., Chow, F. C. C., Choi, D. S., Taneda, S., Hirao, K., Park, Y., Andersen, T. H., Gall, M.-A., & Christiansen, J. S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.026 · Cited by 82
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 92
Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
Heller, S. R., Frier, B. M., Hersløv, M. L., Gundgaard, J., & Gough, S. C. L. (2016) · Diabetic Medicine · doi:10.1111/dme.12844 · Cited by 74
Self-citationClinical use of insulin degludec
Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73
Self-citationGallo, M., Muscogiuri, G., Felicetti, F. C., Faggiano, A., Trimarchi, F., Arvat, E., Vigneri, R., & Colao, A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.013 · Cited by 76
Russell-Jones, D., Gall, M.-A., Niemeyer, M., Diamant, M., & Del Prato, S. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.06.005 · Cited by 66
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P., Lange, M., Frandsen, K. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.004 · Cited by 69
Clinical utility of insulin and insulin analogs
Şanlioğlu, A. D., Altunbaş, H., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2013) · Islets · doi:10.4161/isl.24590 · Cited by 65
Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy
Donner, T. W., & Sarkar, S. (2015) · Europe PMC (PubMed Central) · Cited by 86
Freemantle, N., Chou, E., Frois, C., Zhuo, D., Lehmacher, W., Vlajnic, A., Wang, H., Chung, H.-W., Zhang, Q., Wu, E., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009421 · Cited by 60
Recent Advances in Insulin Therapy
Wilson, L. M., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0065 · Cited by 64
Rodbard, H. W., Gough, S. C. L., Lane, W. S., Korsholm, L., Bretler, D., & Handelsman, Y. (2013) · Endocrine Practice · doi:10.4158/ep13287.or · Cited by 59
Self-citationSorli, C., Warren, M., Oyer, D., Mersebach, H., Johansen, T., & Gough, S. C. L. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0128-2 · Cited by 54
Self-citationBiester, T., Blaesig, S., Remus, K., Aschemeier, B., Kordonouri, O., Granhall, C., Søndergaard, F., Kristensen, N. R., Haahr, H., & Danne, T. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12116 · Cited by 53
Porcellati, F., Lucidi, P., Cioli, P., Candeloro, P., Marinelli Andreoli, A., Marzotti, S., Ambrogi, M., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc14-0649 · Cited by 52
Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review
Zhang, X., Yang, X. Q., Sun, B., & Zhu, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02896-3 · Cited by 60
Riddle, M. C., Bolli, G. B., Home, P. D., Bergenstal, R. M., Ziemen, M., Muehlen-Bartmer, I., Wardecki, M., Vinet, L., Jeandidier, N., & Yki-Järvinen, H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0290 · Cited by 50
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 59
Madenidou, A.-V., Paschos, P., Karagiannis, T., Katsoula, A., Athanasiadou, E., Kitsios, K., Bekiari, E., Matthews, D. R., & Tsapas, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0443 · Cited by 47
Roussel, R., Ritzel, R. A., Corfec, E. B., Balkau, B., & Rosenstock, J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.002 · Cited by 50
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions
Perreault, L., Vincent, L., Neumiller, J. J., & Cavaiola, T. S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.03.180162 · Cited by 49
Haahr, H. L., Fita, E. G., & Heise, T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0455-7 · Cited by 49
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Zhang, X.-W., Zhang, X.-L., Xu, B., & Kang, L.-N. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1107-1 · Cited by 44
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0051-1 · Cited by 46
Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
Kupčová, V., Arold, G., Roepstorff, C., Højbjerre, M., Klim, S., & Haahr, H. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-013-0154-1 · Cited by 40
Kawaguchi, Y., Sawa, J., Sakuma, N., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12884 · Cited by 40
Goldman, J., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38
Freemantle, N., Evans, M., Christensen, T., Wolden, M. L., & Bjørner, J. B. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12086 · Cited by 34
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers
Kuritzky, L., Reid, T., & Wysham, C. (2019) · Clinical Diabetes · doi:10.2337/cd18-0091 · Cited by 40
App-Based Insulin Calculators: Current and Future State
Eiland, L. A., McLarney, M., Thangavelu, T., & Drincic, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1097-y · Cited by 36
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
Kalra, S. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0067-x · Cited by 35
Heller, S., Mathieu, C., Kapur, R., Wolden, M. L., & Zinman, B. (2016) · Diabetic Medicine · doi:10.1111/dme.13002 · Cited by 34
Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L. A., Raskin, P., Zacho, J., Andersen, T. H., & Philis‐Tsimikas, A. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12661 · Cited by 33
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus
Atkin, S. L., Javed, Z., & Fulcher, G. R. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315608646 · Cited by 39
Self-citationWill the next generation of basal insulins offer clinical advantages?
Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12219 · Cited by 33
Ericsson, Å., & Lundqvist, A. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0301-y · Cited by 37
Liu, W., Yang, X., & Huang, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8726046 · Cited by 32
New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl, E., & Owen, D. R. (2016) · Diabetes Care · doi:10.2337/dcs15-3011 · Cited by 35
Cavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 33
Freemantle, N., Mamdani, M., Vilsbøll, T., Kongsø, J. H., Kvist, K., & Bain, S. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0142-y · Cited by 30
Self-citationMehta, R., Goldenberg, R., Katselnik, D., & Kuritzky, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1925148 · Cited by 29
BAJAJ, H. S., Ásbjörnsdóttir, B., Bari, T. J., Begtrup, K., Vilsbøll, T., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15726 · Cited by 33
Self-citationNew Developments in Insulin Therapy for Type 2 Diabetes
SORLI, C. H. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.006 · Cited by 34
Evans, M., Billings, L. K., Håkan‐Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1409228 · Cited by 30
Evans, M., McEwan, P. C., & FOOS, V. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.975234 · Cited by 30
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 26
Zhou, W., Tao, J., Zhou, X., & Chen, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0624-4 · Cited by 31
Type 2 Diabetes Mellitus: Outpatient Insulin Management.
Howard-Thompson, A., Khan, M., Jones, M., & George, C. M. (2018) · PubMed · Cited by 38
Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin
Josse, R. G., & Woo, V. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12114 · Cited by 24
Woo, V. C. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.007 · Cited by 23
Holmes, R. S., Crabtree, E. A., & McDonagh, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13614 · Cited by 24
Demir, T., Turan, S., Ünlühızarcı, K., Topaloğlu, O., Tükek, T., & Yavuz, D. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.616514 · Cited by 22
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 31
Self-citationHarris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 22
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Hompesch, M., Morrow, L., Watkins, E., Roepstorff, C., Thomsen, H. F., & Haahr, H. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.014 · Cited by 20
Maiorino, M. I., Petrizzo, M., Capuano, A., Giugliano, D., & Esposito, K. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.895812 · Cited by 22
Pratley, R. E., Emerson, S. S., Franek, E., Gilbert, M. P., Marso, S. P., McGuire, D. K., Pieber, T. R., Zinman, B., Hansen, C. T., Hansen, M. V., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13699 · Cited by 25
Clinical use of insulin degludec: Practical experience and pragmatic suggestions
Kalra, S., & Gupta, Y. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.153918 · Cited by 22
Type 2 diabetes and cancer: problems and suggestions for best patient management
Milluzzo, A., Vigneri, P. G., Martorana, F., Vigneri, R., & Sciacca, L. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00013 · Cited by 20
Rossetti, P., Ampudia‐Blasco, F. J., & Ascaso, J. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12256 · Cited by 20
Warren, M., CHAYKIN, L. B., Jabbour, S. A., Sheikh‐Ali, M., Hansen, C. T., Nielsen, T. S. S., & Norwood, P. C. (2017) · Clinical Diabetes · doi:10.2337/cd15-0058 · Cited by 20
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
Miccoli, R., Dardano, A., Bianchi, C., & Prato, S. D. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40097 · Cited by 19
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
Hughes, E. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2015.12.005 · Cited by 18
EINHORN, D. F., Handelsman, Y., Bode, B. W., Endahl, L. A., Mersebach, H., & King, A. B. (2015) · Endocrine Practice · doi:10.4158/ep14523.or · Cited by 18
Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
Chan, W. B., Chen, J.-F., Goh, S., Vũ, T. T. H., Isip-Tan, I. T., Mudjanarko, S. W., Bajpai, S., Mabunay, M. A., & Bunnag, P. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s143046 · Cited by 19
Concepts and clinical use of ultra-long basal insulin
Eliaschewitz, F. G., & Barreto, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0117-1 · Cited by 20
Pollock, R. F., & Tikkanen, C. K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1245663 · Cited by 20
Drab, S. R., & Philis‐Tsimikas, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1361 · Cited by 18
the RESTORE-1 Study Group, Laviola, L., Porcellati, F., Bruttomesso, D., Larosa, M., Rossi, M. C., & Nicolucci, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00982-z · Cited by 16
CHENG, A. Y. Y., Bailey, T. S., Mauricio, D., & Roussel, R. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3329 · Cited by 17
Pfützner, A., Forst, T. M., Niemeyer, M., & Bailey, T. S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927438 · Cited by 17
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 18
Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
Lindauer, K., & Becker, R. H. A. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203269 · Cited by 18
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
Patel, D. K., Triplitt, C. L., & Trujillo, J. M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00907-8 · Cited by 17
Su, W., Li, C., Zhang, L., Lin, Z., Tan, J. H., & Xuan, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00683-2 · Cited by 19
Haluzík, M., Fulcher, G., Pieber, T. R., Bardtrum, L., Tutkunkardas, D., & Rodbard, H. W. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13261 · Cited by 17
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
Kumar, A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.904851 · Cited by 17
Drummond, R. S., Malkin, S. J. P., Preez, M. D., Lee, X. Y., & Hunt, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13375 · Cited by 16
Metadata
- Authors
- Meneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., & on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators
- Affiliations
- University of Miami (US)
- Hull York Medical School (GB)
- Churchill Hospital (GB)
- Hadassah Medical Center (IL)
- Ochsner Health System (US)
- Endocrinology Research Center (RU)
- Singleton Hospital (GB)
- Novo Nordisk (Denmark) (DK)
- Oslo University Hospital (NO)
- Corresponding author
- Meneghini, Luigi
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-03-14
- Volume
- 36
- Issue
- 4
- Pages
- 858-864
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3609505
- OpenAlex
- W2146026006
- Semantic Scholar
- 26c9a57c740ae859eaa21ee58bc49f8d9da1fc6d
- Cited by
- 226
- References
- 26
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 10 · 2020: 11 · 2019: 20 · 2018: 31 · 2017: 21 · 2016: 29 · 2015: 27 · 2014: 34 · 2013: 22
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, insulin glargine, basal insulin analogues, type 2 diabetes, injection timing, glycemic control, HbA1c, hypoglycemia, non-inferiority
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.